Biopharma Company Sues DEA for 'Unjustified Delays' in Approving Cannabis Research
MMJ BioPharma Cultivation sues DEA for delays in cannabis research approval for MS and HD treatments, alleging financial harm and patient suffering. The lawsuit questions DEA's use of Administrative Law Judges and accuses DEA Administrator Anne Milgram of bias against cannabis research.
Reference News
MMJ BioPharma Cultivation sues DEA over delays in processing its application to grow marijuana for pharmaceutical research, hindering clinical trials for conditions like MS and HD. CEO Duane Boise highlights the impact on cultivating specific cannabis strains and investor deterrence, despite developing a soft gelatin capsule awaiting FDA approval. The lawsuit raises constitutional issues regarding the DEA's ALJ process and aligns with recent Supreme Court rulings, emphasizing MMJ's commitment to a long-term legal fight.
MMJ BioPharma Cultivation sues DEA for delays in cannabis research approval for MS and HD treatments, alleging financial harm and patient suffering. The lawsuit questions DEA's use of Administrative Law Judges and accuses DEA Administrator Anne Milgram of bias against cannabis research.